Alzheon is a privately held clinical stage, biotechnology company based in Framingham, Massachusetts that was founded in 2013 by Martin Tolar. It focuses on developing medications by directly addressing the underlying pathology of neurodegenerative disorders.
The company's lead product candidate is ALZ-801, a patented, orally administered prodrug of tramiprosate that is designed to inhibit amyloid oligomer formation, a key driver of Alzheimer's disease.
The product is intended to focus on patients with mild Alzheimer's with the APOE4 genotype. It has been granted Fast Track Designation by the FDA in October 2017. Phase 3 clinical trials are planned for 2019.
Alzheon's product pipeline also has ALZ-1903, a pre-clinical candidate with the potential to inhibit amyloid misfolding.
On January 9, 2015 Alzheon completed a venture capital round with $3.1 million in funding from undisclosed investors.
On April 8, 2015 Alzheon completed their series A funding round with $10 million in funding from Ally Bridge Group (lead investor) and Scott H. Cohen.
On June 9, 2017 Alzheon is a completed their series B funding round with $15.8 million in funding from Ally Bridge Group.
Initial public offering
In April 2018, the company planned an $80 million IPO, but soon withdrew the offer. It re-announced later in August a $40 million IPO. However, that too was withdrawn in January 2019.
VP, Program and Portfolio Management
Chief Scientific Officer
Founder, President & CEO
Chief Medical Officer
Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease, Further Supporting Precision Medicine Approach and Planned Confirmatory Clinical Trial with ALZ-801
What Happened? Alzheon Leaves IPO on the Table for the Second Time | BioSpace
Documentaries, videos and podcasts
- Alzheimer's diseaseChronic neurodegenerative disease that usually starts slowly and worsens over time. it is the cause of 60% to 70% of cases of dementia
- BiotechnologyBiolotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.